Surface Oncology

General Information


We are a clinical-stage immuno-oncology company focused on using our specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment, or the TME, for the development of next-generation cancer therapies. While first-generation immuno-oncology therapies, such as checkpoint inhibitors, are a remarkable therapeutic advancement, we believe most patients do not achieve durable clinical benefit primarily because these therapies focus on only one element of the complex and interconnected immunosuppressive TME. We believe there is a significant opportunity to more broadly engage the body’s immune system in a multi-faceted, coordinated and personalized approach, to meaningfully improve cure rates for patients with a variety of cancers.


Employees: 56
Founded: 2014
Contact Information
Address 50 Hampshire Street, 8th Floor, Cambridge, MA 02139, US
Phone Number (617) 714-4096.
Web Address
View Prospectus: Surface Oncology
Financial Information
Market Cap $413.95mil
Revenues $12.8 mil (last 12 months)
Net Income $-45.4 mil (last 12 months)
IPO Profile
Symbol SURF
Exchange NASDAQ
Shares (millions): 7.2
Price range $15.00 - $15.00
Est. $ Volume $108.0 mil
Manager / Joint Managers Goldman Sachs/ Cowen/ Evercore ISI
CO-Managers -
Expected To Trade: 4/19/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change